Wednesday, 27 October 2010

Rebif delays conversion to MS in patients with first clinical signs of the disease

From the MSRC:
 Merck Serono, a division of Merck KGaA,Darmstadt, Germany, announced that the two-year Phase III REFLEX 1 study met its primary endpoint by demonstrating that Rebif® (interferon beta-1a) significantly delayed conversion to multiple sclerosis (MS) diagnosed according to the McDonald criteria 2 in patients with a first clinical event suggestive of the disease.  Read more click here and scroll down page.